Adimab alternatives
10 products to explore · 2026
Your shortlist, at a glance.
Read the comparisons ↓Check each product’s website for current pricing and features. A verified badge indicates a verified listing, not a ranking.
About Adimab and its alternatives
Professionals searching for Adimab alternatives typically need yeast-display antibody platforms that emphasize developability, multispecific formats and flexible partnering without an internal pipeline. Adimab’s model centers on fully human libraries, high-throughput sorting and real-time engineering to produce stable IgGs and T-cell engagers ready for clinical advancement. Competitors range from phage-display specialists to mammalian-display or AI-driven services that may offer different library depths, turnaround times or licensing structures. When evaluating options, teams compare success rates in generating developable leads, access to multispecific technologies, and whether the provider runs funded programs or simply sells platform access. Adimab’s track record of 90+ clinical-stage programs and six approved products provides a benchmark for partners prioritizing clinical translation over tool-only offerings.
Explore the alternatives
- A
1.Abalone Bio
Healthcare & MedicalWe create activating antibodies to treat diseases others can’t.
- A
2.AbCellera
Healthcare & MedicalPlatform for discovering and developing first-in-class antibody medicines
3.Absci
Healthcare & MedicalUnlocking novel biology and creating better biologics with AI
- A
4.Agenus
Healthcare & MedicalAgenus: Better immunotherapies
5.Genmab
Healthcare & MedicalWelcome to Genmab
- H
6.Harbour BioMed
Healthcare & Medical 
7.MorphoSys
Healthcare & MedicalWorking together, we can reimagine medicine to improve and extend people’s lives.
8.Sorrento Therapeutics
Healthcare & MedicalAdvancing a pipeline of novel therapeutics
9.Twist Bioscience
Healthcare & MedicalSilicon-based DNA synthesis, genes, oligos, NGS panels and variant libraries
10.Xencor
Healthcare & MedicalXmAb protein engineering platform for bispecific antibody therapeutics in oncology
See more comparisons in Healthcare & Medical alternatives.
Questions about Adimab alternatives
What makes Adimab’s yeast platform different from phage-display antibody services?
Adimab uses yeast display with integrated developability screening and real-time affinity maturation, whereas many phage systems require additional mammalian reformatting steps that can reduce stability or expression.
How do Adimab funded discovery programs compare to platform-transfer alternatives?
Funded discovery lets partners receive preclinical leads without building internal capability, while platform transfer grants full in-house access to Adimab’s libraries and protocols for ongoing programs.
Which Adimab capabilities support multispecific T-cell engager development?
Adimab engineers diverse multispecific formats including T-cell engagers with emphasis on function, manufacturability and scalability using its yeast-based screening workflow.
Does Adimab require upfront fees or milestone payments for discovery projects?
Adimab structures collaborations through funded discovery, platform transfer or non-exclusive licensing; exact terms are customized and discussed directly with partners.
How many Adimab-derived antibodies have reached commercial approval?
Six commercial products have originated from Adimab’s platform across its 140+ partnerships and 675+ initiated programs.
Can Adimab’s TCR engineering service replace traditional protein engineering CROs?
Adimab applies AI-guided yeast display to soluble TCRs and other non-antibody proteins, offering an integrated alternative for partners needing both binding and developability optimization.